US Pharm.
2007;32(10):71.
Omega-3 Fatty Acids Reduce Risk
of Type 1 Diabetes in Children
Preliminary
research published in a recent issue of JAMA suggests that the dietary
intake of omega-3 fatty acids by children at increased genetic risk for type 1
diabetes is associated with a reduced risk of pancreatic islet autoimmunity,
which is linked to the development of this disease.
According to the authors,
"Type 1 diabetes mellitus is an autoimmune disease that is characterized by
the destruction of insulin-producing beta cells in the pancreatic islets.
Although it is not yet known what initiates the autoimmune process, it is
likely that both genetic background and environmental factors contribute to
the disease process."
ED Drug Useful in Men with
Spinal Cord Injury
Researchers at
Raymond Pointcaré Hospital in Garche, France, reported that tadalafil may help
some men with erectile dysfunction secondary to spinal cord injury have
erections sufficient for satisfactory sex compared to those who took a placebo.
The results, published in the
Archives of Neurology, reported on a group of men who took tadalafil and
had a significantly higher mean per-patient percentage of successful
penetration attempts compared to the placebo group. The drug group also had a
significantly higher percentage of successful intercourse attempts and greater
frequency of ejaculation. The patients' ages ranged from 18 to 36.
Vitamin D Linked to a
Reduction in Mortality
While the medical
literature is full of praises for vitamin D for improving bone health, a
meta-analysis of 18 randomized trials found that it may also reduce all-cause
mortality by a small but statistically significant degree.
The findings, which were
published in the Archives of Internal Medicine, showed an 8% reduction
in all-cause mortality when vitamin D was taken daily for three or more years.
According to Philippe Autier, MD, of the International Agency for Research on
Cancer in Lyon, France, and coauthor Sara Gandini, PhD, of the European
Institute of Oncology in Milan, Italy, while the mechanisms by which vitamin D
would decrease mortality are not clear, there are several possibilities. One
such possibility is that some effects of activation of the vitamin D receptor
"such as inhibition of cellular proliferation and activation of cellular
differentiation, could reduce aggressiveness of cancerous processes and
expansion of atheromatous lesions."
The authors conclude that
"population-based, placebo-controlled randomized trials in people 50 years or
older for at least six years with total mortality as the main end point should
be organized to confirm these findings."
Tamoxifen May Be Effective
in Some Bipolar Patients
A small pilot study
showed that tamoxifen, approved to treat breast cancer, may be effective in
significantly decreasing symptoms of acute mania in patients with bipolar
disorder as early as five days after beginning treatment.
According to Carlos A. Zarate, Jr., MD, of
the National Institute of Mental Health, and colleagues, tamoxifen maintained
its effect throughout a three-week trial with a response rate of 63% compared
to 13% for a placebo. The results were published online in Bipolar
Disorders.
The authors reasoned that
tamoxifen, a relatively selective protein kinase C inhibitor with the
advantage that it crosses the blood–brain barrier, would produce antimanic
effects more rapidly than previously achieved with lithium or valproate. They
said that lithium and valproate exert their effects "considerably upstream of
protein kinase C" and ultimately work more indirectly than tamoxifen. Another
advantage of tamoxifen, according to the researchers, is that it responds more
rapidly than drugs that are traditionally used to treat mania in bipolar
disorder. However, they caution that it is important to take into
consideration the risk-to-benefit ratio, as tamoxifen may cause endometrial
cancer if taken for extended periods.
The authors caution that the
results of this relatively small study need to be interpreted with care. Also,
the results may not be generalized to patients with certain characteristics;
for example, those with current substance abuse disorders. They also conclude
that the results may not apply beyond the acute-treatment phase of bipolar
mania.
To comment on this article,
contact editor@uspharmacist.com.